Rani Therapeutics Holdings Stock News

Gainers: Weidai (WEI) +79%.Rani Therapeutics Holdings (RANI) +33%.Stride LRN +29%.Exela Technologies XELA +26%.Huadi International (HUDI) +21%.Koss (KOSS) +20%.Sierra (SRRA)

Rani Therapeutics (NASDAQ:RANI) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability. Analyst Recommendations This is a breakdown of current ratings and recommmendations for Rani Therapeutics and Soligenix, […]

Shares of Rani Therapeutics Holdings Inc (NASDAQ:RANI) have been assigned an average recommendation of Buy from the six research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12-month price target among brokerages []

Rani Therapeutics Holdings Inc (NASDAQ:RANI)s stock price gapped down before the market opened on Friday . The stock had previously closed at $16.94, but opened at $16.18. Rani Therapeutics shares last traded at $16.88, with a volume of 201 shares. Several equities research analysts have commented on the company. Stifel Nicolaus assumed coverage on Rani []

Rani Therapeutics Holdings Inc (NASDAQ:RANI) – Equities researchers at Cantor Fitzgerald lowered their FY2021 EPS estimates for Rani Therapeutics in a research note issued to investors on Monday, December 6th. Cantor Fitzgerald analyst B. Folkes now forecasts that the company will earn ($1.19) per share for the year, down from their prior estimate of ($0.76). […]

Rani Therapeutics Holdings Inc (NASDAQ:RANI) shares gapped down prior to trading on Friday . The stock had previously closed at $25.68, but opened at $24.52. Rani Therapeutics shares last traded at $24.51, with a volume of 714 shares traded. A number of brokerages have recently commented on RANI. BTIG Research began coverage on Rani Therapeutics […]

Rani Therapeutics (NASDAQ:RANI) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research note issued on Friday, Zacks.com reports. According to Zacks, Rani Therapeutics Holdings Inc. is a clinical stage biotherapeutics company. It focused on advancing technologies to enable the development of orally administered biologics. Rani Therapeutics Holdings []

Shares of Rani Therapeutics Holdings Inc (NASDAQ:RANI) have received a consensus recommendation of Buy from the six analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among brokerages []

Rani Therapeutics Holdings Inc (NASDAQ:RANI)s share price gapped down before the market opened on Monday . The stock had previously closed at $34.06, but opened at $33.00. Rani Therapeutics shares last traded at $30.89, with a volume of 201 shares trading hands. RANI has been the subject of several research analyst reports. Stifel Nicolaus initiated []

Rani Therapeutics Holdings Inc (NASDAQ:RANI)s share price hit a new 52-week high on Tuesday after the company announced better than expected quarterly earnings. The company traded as high as $36.27 and last traded at $30.10, with a volume of 228981 shares changing hands. The stock had previously closed at $29.07. The company reported ($0.16) earnings []

A game-changing pill from Rani Therapeutics may offer an easier alternative to fight debilitating diseases.

SAN JOSE, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the comp

- IPO in July 2021 raised $84.3 million in gross proceeds - - Talat Imran Appointed Chief Executive Officer - - Enhanced leadership team with key management and board of directors' appointments -

The markets were higher across the board near midday, after a strong two-day rally opened the trading week.

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), an early stage platform technology company that promotes oral dosing with its RaniPill, and RxSight, Inc. (NASDAQ:RXST), an ophthalmology-focused MedTec